Sarepta Therapeutics: Next Steps After Full FDA Approval for Duchenne Muscular Dystrophy Gene Therapy

Sarepta Therapeutics, Duchenne muscular dystrophy, gene therapy, FDA approval, Elevidys, microdystrophin, ambulatory patients, non-ambulatory patients, pipeline development, rare diseases, genetic medicine.

CDMO Leaders Unite for Turn-key Drug Production

Contract Development and Manufacturing Organizations (CDMOs), pharmaceutical supply chain, advanced therapies, strategic partnerships, end-to-end services, technology innovation, market consolidation, and competitive advantage.